0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-12-01 Sage Accounts Production Advanced 2024 - FRS102_2024 9,840 9,096 xbrli:pure xbrli:shares iso4217:GBP 08295361 2023-12-01 2025-05-31 08295361 2025-05-31 08295361 2023-11-30 08295361 2022-12-01 2023-11-30 08295361 2023-11-30 08295361 2022-11-30 08295361 bus:RegisteredOffice 2023-12-01 2025-05-31 08295361 bus:Director1 2023-12-01 2025-05-31 08295361 core:WithinOneYear 2025-05-31 08295361 core:WithinOneYear 2023-11-30 08295361 core:ShareCapital 2025-05-31 08295361 core:ShareCapital 2023-11-30 08295361 core:RetainedEarningsAccumulatedLosses 2025-05-31 08295361 core:RetainedEarningsAccumulatedLosses 2023-11-30 08295361 bus:SmallEntities 2023-12-01 2025-05-31 08295361 bus:AuditExempt-NoAccountantsReport 2023-12-01 2025-05-31 08295361 bus:SmallCompaniesRegimeForDirectorsReport 2023-12-01 2025-05-31 08295361 bus:PrivateLimitedCompanyLtd 2023-12-01 2025-05-31 08295361 bus:FullAccounts 2023-12-01 2025-05-31
COMPANY REGISTRATION NUMBER: 08295361
Norman Epstein Consulting Limited
Unaudited Financial Statements
31 May 2025
Norman Epstein Consulting Limited
Director's Report
Period from 1 December 2023 to 31 May 2025
The director presents his report and the unaudited financial statements of the company for the period ended 31 May 2025 .
Director
The director who served the company during the period was as follows:
Mrs K Kay
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on 23 June 2025 and signed on behalf of the board by:
Mrs K Kay
Director
Registered office:
18 Kingsley Avenue
Borehanwood
Hertfordshire
England
WD6 4LY
Norman Epstein Consulting Limited
Statement of Income and Retained Earnings
Period from 1 December 2023 to 31 May 2025
Period from
1 Dec 23 to
Year to
31 May 25
30 Nov 23
Note
£
£
Administrative expenses
9,840
9,096
-------
-------
Operating loss
4
( 9,840)
( 9,096)
-------
-------
Loss before taxation
( 9,840)
( 9,096)
Tax on loss
-------
-------
Loss for the financial period and total comprehensive income
( 9,840)
( 9,096)
-------
-------
All the activities of the company are from continuing operations.
Norman Epstein Consulting Limited
Statement of Financial Position
31 May 2025
31 May 25
30 Nov 23
Note
£
£
Current assets
Cash at bank and in hand
73,759
Creditors: amounts falling due within one year
6
28,895
92,814
--------
--------
Net current liabilities
28,895
19,055
--------
--------
Total assets less current liabilities
( 28,895)
( 19,055)
--------
--------
Net liabilities
( 28,895)
( 19,055)
--------
--------
Capital and reserves
Called up share capital
7
1
1
Profit and loss account
( 28,896)
( 19,056)
--------
--------
Shareholders deficit
( 28,895)
( 19,055)
--------
--------
For the period ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.
These financial statements were approved by the board of directors and authorised for issue on 23 June 2025 , and are signed on behalf of the board by:
Mrs K Kay
Director
Company registration number: 08295361
Norman Epstein Consulting Limited
Statement of Cash Flows
Period from 1 December 2023 to 31 May 2025
31 May 25
30 Nov 23
£
£
Cash flows from operating activities
Loss for the financial period
( 9,840)
( 9,096)
Adjustments for:
Accrued (income)/expenses
( 5,076)
80
Changes in:
Trade and other creditors
( 58,843)
17,916
--------
--------
Cash generated from operations
( 73,759)
8,900
--------
-------
Net cash (used in)/from operating activities
( 73,759)
8,900
--------
-------
Net (decrease)/increase in cash and cash equivalents
( 73,759)
8,900
Cash and cash equivalents at beginning of period
73,759
64,859
--------
--------
Cash and cash equivalents at end of period
73,759
--------
--------
Norman Epstein Consulting Limited
Notes to the Financial Statements
Period from 1 December 2023 to 31 May 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 18 Kingsley Avenue, Borehanwood, Hertfordshire, WD6 4LY, England.
2. Statement of compliance
These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Operating loss
Operating profit or loss is stated after charging:
Period from
1 Dec 23 to
Year to
31 May 25
30 Nov 23
£
£
Foreign exchange differences
666
----
----
5. Staff costs
The average number of persons employed by the company during the period, including the director, amounted to:
31 May 25
30 Nov 23
No.
No.
The aggregate payroll costs incurred during the period, relating to the above, were:
Period from
1 Dec 23 to
Year to
31 May 25
30 Nov 23
£
£
Wages and salaries
7,149
7,800
-------
-------
6. Creditors: amounts falling due within one year
31 May 25
30 Nov 23
£
£
Trade creditors
28,895
87,738
Accruals and deferred income
5,076
--------
--------
28,895
92,814
--------
--------
7. Called up share capital
Issued, called up and fully paid
31 May 25
30 Nov 23
No.
£
No.
£
8. Analysis of changes in net debt
At 1 Dec 2023
Cash flows
At 31 May 2025
£
£
£
Cash at bank and in hand
73,759
(73,759)
--------
--------
----